236 related articles for article (PubMed ID: 17560331)
1. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.
Liu Y; Chen W; Gaudet J; Cheney MD; Roudaia L; Cierpicki T; Klet RC; Hartman K; Laue TM; Speck NA; Bushweller JH
Cancer Cell; 2007 Jun; 11(6):483-97. PubMed ID: 17560331
[TBL] [Abstract][Full Text] [Related]
2. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.
Liu Y; Cheney MD; Gaudet JJ; Chruszcz M; Lukasik SM; Sugiyama D; Lary J; Cole J; Dauter Z; Minor W; Speck NA; Bushweller JH
Cancer Cell; 2006 Apr; 9(4):249-60. PubMed ID: 16616331
[TBL] [Abstract][Full Text] [Related]
3. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
4. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.
Corpora T; Roudaia L; Oo ZM; Chen W; Manuylova E; Cai X; Chen MJ; Cierpicki T; Speck NA; Bushweller JH
J Mol Biol; 2010 Sep; 402(3):560-77. PubMed ID: 20708017
[TBL] [Abstract][Full Text] [Related]
5. CBFbeta is critical for AML1-ETO and TEL-AML1 activity.
Roudaia L; Cheney MD; Manuylova E; Chen W; Morrow M; Park S; Lee CT; Kaur P; Williams O; Bushweller JH; Speck NA
Blood; 2009 Mar; 113(13):3070-9. PubMed ID: 19179469
[TBL] [Abstract][Full Text] [Related]
6. Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
Chen-Wichmann L; Shvartsman M; Preiss C; Hockings C; Windisch R; Redondo Monte E; Leubolt G; Spiekermann K; Lausen J; Brendel C; Grez M; Greif PA; Wichmann C
Oncogene; 2019 Jan; 38(2):261-272. PubMed ID: 30093631
[TBL] [Abstract][Full Text] [Related]
7. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
Gelmetti V; Zhang J; Fanelli M; Minucci S; Pelicci PG; Lazar MA
Mol Cell Biol; 1998 Dec; 18(12):7185-91. PubMed ID: 9819405
[TBL] [Abstract][Full Text] [Related]
8. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.
Yan M; Burel SA; Peterson LF; Kanbe E; Iwasaki H; Boyapati A; Hines R; Akashi K; Zhang DE
Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17186-91. PubMed ID: 15569932
[TBL] [Abstract][Full Text] [Related]
9. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.
Racanicchi S; Maccherani C; Liberatore C; Billi M; Gelmetti V; Panigada M; Rizzo G; Nervi C; Grignani F
EMBO J; 2005 Mar; 24(6):1232-42. PubMed ID: 15729358
[TBL] [Abstract][Full Text] [Related]
10. The role of CBFbeta in AML1-ETO's activity.
Park S; Speck NA; Bushweller JH
Blood; 2009 Sep; 114(13):2849-50. PubMed ID: 19779050
[No Abstract] [Full Text] [Related]
11. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
[TBL] [Abstract][Full Text] [Related]
12. The role of CBFbeta in AML1-ETO's activity.
Kwok C; Zeisig BB; Dong S; So CW
Blood; 2010 Apr; 115(15):3176-7. PubMed ID: 20395424
[No Abstract] [Full Text] [Related]
13. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.
Wang J; Hoshino T; Redner RL; Kajigaya S; Liu JM
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10860-5. PubMed ID: 9724795
[TBL] [Abstract][Full Text] [Related]
14. Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival.
Dayyani F; Wang J; Yeh JR; Ahn EY; Tobey E; Zhang DE; Bernstein ID; Peterson RT; Sweetser DA
Blood; 2008 Apr; 111(8):4338-47. PubMed ID: 18258796
[TBL] [Abstract][Full Text] [Related]
15. Definition of a small core transcriptional circuit regulated by AML1-ETO.
Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
[TBL] [Abstract][Full Text] [Related]
16. Chaperonin TRiC/CCT Recognizes Fusion Oncoprotein AML1-ETO through Subunit-Specific Interactions.
Roh SH; Kasembeli MM; Galaz-Montoya JG; Chiu W; Tweardy DJ
Biophys J; 2016 Jun; 110(11):2377-2385. PubMed ID: 27276256
[TBL] [Abstract][Full Text] [Related]
17. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
[TBL] [Abstract][Full Text] [Related]
18. Oligomerization of ETO is obligatory for corepressor interaction.
Zhang J; Hug BA; Huang EY; Chen CW; Gelmetti V; Maccarana M; Minucci S; Pelicci PG; Lazar MA
Mol Cell Biol; 2001 Jan; 21(1):156-63. PubMed ID: 11113190
[TBL] [Abstract][Full Text] [Related]
19. Domains involved in ETO and human N-CoR interaction and ETO transcription repression.
Wang J; Wang M; Liu JM
Leuk Res; 2004 Apr; 28(4):409-14. PubMed ID: 15109542
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.
DeKelver RC; Yan M; Ahn EY; Shia WJ; Speck NA; Zhang DE
Blood; 2013 May; 121(18):3714-7. PubMed ID: 23426948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
